India’s pharmaceutical sector, long considered a reliable growth engine in the country’s export landscape, is now staring at a potential disruption. A recent report from Fitch Ratings has raised red flags over the industry’s exposure to escalating trade tensions between India and the United States.

The US, which accounts for a significant portion of India’s pharmaceutical exports, has recently introduced a wave of new tariffs. While most sectors have so far experienced minimal direct impact, Fitch has singled out pharmaceuticals as being particularly vulnerable to future policy shifts.

India’s Drug Exports at Risk Amid Rising Protectionism

India supplies a substantial share of low-cost generic drugs to the United States, helping to reduce overall healthcare costs for American consumers. But this close relationship also means that Indian companies are deeply dependent on the US market.

According to Fitch, if Washington decides to include pharmaceutical goods in its list of tariffed items, the impact could be swift and severe. Higher duties could make Indian-made medicines less competitive, squeeze profit margins, and force companies to reassess their supply chains and global strategies.

Biocon and Others Stand Exposed

One of the companies most at risk is Biocon Biologics, which earns close to 40% of its revenue from the US. The firm manufactures the bulk of its biosimilar products in India and Malaysia, meaning any tariff on drug imports could significantly increase costs and impact profitability.

Smaller firms and mid-sized players in the pharmaceutical industry may be even less equipped to handle such shifts. Many operate in high-volume, low-margin segments where absorbing additional costs or raising prices could be unfeasible in an already competitive global market.

Recent US Moves Raise Concerns

The warning from Fitch follows a string of recent US actions that have already rattled Indian exporters. These include:

• A 25% reciprocal tariff on Indian-origin goods that took effect on August 7, 2025.
• A second 25% tariff targeting items linked to imports of Russian crude oil, scheduled to begin August 27.

While pharmaceuticals have not yet been directly affected, the sector’s sensitivity and strategic importance make it a likely target in future rounds of trade enforcement.

Broader Industry Sentiment and Economic Implications

Beyond pharmaceuticals, other sectors such as automotive components and chemicals also face potential risk. However, companies like Samvardhana Motherson, with US-based production units, are better positioned to navigate the turbulence.

Fitch also notes that if trade pressures remain elevated and tariffs continue to rise, India’s GDP growth forecast of 6.5% for FY26 could face downward revision. Prolonged tensions may dampen investor confidence and disrupt export-driven industries.

Indian Pharma’s Strategic Dilemma

The pharmaceutical sector is already responding to the possibility of trade restrictions by exploring new strategies:

• Diversification of markets, shifting focus toward Europe, Latin America, and Africa.
• Establishing manufacturing hubs abroad, including in the US, to avoid tariff-related cost hikes.
• Portfolio optimization, moving away from low-margin generics and into higher-value drugs and specialty treatments.

Industry experts believe that this period of uncertainty could ultimately accelerate innovation and efficiency within Indian pharma. However, the immediate challenge is clear: mitigating short-term risks while maintaining global market share.

The American Consumer Could Also Feel the Pinch

It’s worth noting that the tariff threat isn’t just an Indian concern. If Indian generics become more expensive due to trade barriers, the cost of medicines in the US could rise. Indian pharmaceuticals have saved the US healthcare system billions of dollars over the past decade—an advantage that could diminish if tariffs increase.

Any attempt by Washington to curb drug imports without adequate alternatives in place could backfire, especially in a year marked by economic sensitivity and political volatility.

Conclusion: Pharma’s Crossroads Between Policy and Profit

India’s pharmaceutical sector is entering a period of heightened uncertainty. With so much riding on stable trade with the US, the stakes have never been higher. Fitch’s warning underscores the need for rapid adaptation, strategic diversification, and diplomatic engagement to ensure Indian pharma continues to thrive in a changing global trade landscape.

As global trade policies shift, Indian drugmakers must be ready to pivot—because resilience, not reliance, will define the next chapter of their international journey.